Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma

Ye Chen1, Liang Xu1, Anand Mayakonda1, Mo-Li Huang1,2, Deepika Kanojia1, Tuan Zea Tan1, Pushkar Dakle3, Ruby Yu-Tong Lin1, Xin-Yu Ke1, Jonathan W. Said3, Jianxiang Chen4, Sigal Gery5, Ling-Wen Ding1, Yan-Yi Jiang1, Angela Pang6, Mark Edward Puhaindran6,7,8, Boon Cher Goh1,6,9 & H. Phillip Koeffler1,5,6

Liposarcomas (LPSs) are a group of malignant mesenchymal tumors showing adipocytic differentiation. Here, to gain insight into the enhancer dysregulation and transcriptional addiction in this disease, we chart super-enhancer structures in both LPS tissues and cell lines. We identify a bromodomain and extraterminal (BET) protein-cooperated FUS-DDIT3 function in myxoid LPS and a BET protein-dependent core transcriptional regulatory circuitry consisting of FOSL2, MYC, and RUNX1 in de-differentiated LPS. Additionally, SNAI2 is identified as a crucial downstream target that enforces both proliferative and metastatic potentials to de-differentiated LPS cells. Genetic depletion of BET genes, core transcriptional factors, or SNAI2 mitigates consistently LPS malignancy. We also reveal a compelling susceptibility of LPS cells to BET protein degrader ARV-825. BET protein depletion confers additional advantages to circumvent acquired resistance to Trabectedin, a chemotherapy drug for LPS. Moreover, this study provides a framework for discovering and targeting of core oncogenic transcriptional programs in human cancers.
Transcription factors (TFs) coordinate the expression of target genes typically through cis-regulatory DNA elements. A small set of lineage-specific master TFs and/or de novo chimeric fusion TFs dictate the core transcriptional programs governing cell identity and malignant state. Elucidating the core transcriptional regulatory mechanisms is necessary to understand the fundamentals of molecular carcinogenesis.

Liposarcomas (LPSs) are a group of mesenchymal malignancies showing adipocytic differentiation and are the prevailing types of soft tissue sarcomas in adults. LPSs are heterogeneous diseases with four major subtypes: well-differentiated LPS (WDLPS), de-differentiated LPS (DDLPS), myxoid LPS (MLPS), and pleomorphic LPS (PLPS). The latter three comprise the majority of high-grade cases. DDLPS and PLPS are largely refractory to current treatment modalities, while MLPS shows generally better clinical response and prognosis. Although recent approval of Trabectedin (Yondelis) for LPS treatment offers a new option of systematic chemotherapy agent, durable efficacy of Trabectedin for LPS is not type and repression of KLF6. To date, although BET bromodomain inhibitors (BBIs) have been shown extensively to disrupt the SE activity and display pro-apoptotic effects25, the function of BET proteins and histone acetyltransferases (HATs) has been only briefly considered. A small set of lineage-specific master regulators22,23. As little is known about enhancer dysregulation in liposarcomagenesis, uncovering the SE architectures will be important to improve the current understanding of epigenetic mechanism underlying LPS malignancy. SE regions are bound asymetrically by BRD4, one of the bromodomains and extraterminal (BET) family proteins that read histone lysine acetylation and co-activate key oncogenic transcription. To date, although BET bromodomain inhibitors (BBIs) have been shown extensively to disrupt the SE activity and display promising anti-cancer effects25, the function of BET proteins and their druggability in LPS are still unexplored.

The current study was designed to elaborate the BET protein dependency and its mechanistic connections to the aberrant enhancer states and core transcriptional programs in LPS. We demonstrate that (1) BET proteins are vital to maintain the DDLPS-specific core transcriptional regulatory circuitry consisting of SE-associated TFs FOSL2, MYC, and RUNX1; and (2) BRD4 is a novel co-activator for FUS-DDIT3 function in MLPS. We also report the superior anti-LPS efficacy of BET protein-degrading agents, which provides important insights to targeted depletion of BET proteins as a candidate therapeutic approach for LPS.

Results

Charting the super-enhancer landscape in DDLPS and MLPS.

To evaluate the active epigenetic states associated with LPS malignancy, we performed chromatin immunoprecipitation followed by next-generation sequencing (ChIP-seq) of histone mark H3K27ac in both LPS cell lines and primary tumors. We first compared the H3K27ac-inferred SE architectures in mesenchymal stem cells (MSCs), mature adipocytes, and cells derived from MLPS and DDLPS (Fig. 1a and Supplementary Fig. 1). SE association captured the vast majority of highly expressed genes, which can distinguish differentiation stages, disease states, and subtypes of these cells (Fig. 1b and Supplementary Fig. 2a–c). LPS cells engaged preferentially SEs to genes involved in cancer pathways, as well as biological processes of development, cell migration, angiogenesis and transcription from RNA-Pol2 promoter (Supplementary Fig. 2d, e). In contrast, SE-associated genes that were exclusive to adipocytes (e.g., CEBPA and PPARG) were enriched in PPAR signaling pathway (Fig. 1c and Supplementary Table 1). Of note, we also mapped the SE structures in primary tumors and found that MLPS and DDLPS tissues had 25% and 33% of SE-associated genes overlapping, respectively, with LPS cell lines of the same subtype (Fig. 1d–f and Supplementary Table 2). Altogether, these data are insightful for molecular pathogenesis of LPS, and motivate us to explore the disease-specific gene regulation in MLPS and DDLPS.

Occupancy of FUS-DDIT3 across super-enhancers in MLPS.

The preferential association of SEs to genes regulating RNA-Pol2 activity prompted us to interrogate potential transcriptional addiction. MLPS manifests core dependency on FUS-DDIT3 (Fig. 2a and Supplementary Fig. 3a–d). Genome-wide occupancy analysis indicated that about 9% of FUS-DDIT3 peaks bound active promoters with broader RNA-Pol2 loading and higher transcription (Fig. 2b, c and Supplementary Fig. 3e, f). Moreover, nearly 60% of FUS-DDIT3 peaks were mapped to putative enhancers, including 97% of H3K27ac-defined SEs and 62% of typical enhancers. Interestingly, the intensity of FUS-DDIT3 peaks was enhanced moderately but significantly inside SEs, coincided with elevated permissive histone marks (Fig. 2d and Supplementary Fig. 3g). FUS-DDIT3 loading in SE was strongly associated with low promoter-proximal pausing of RNA-Pol2 in target genes (Supplementary Fig. 3h). By stitching the peaks of FUS-DDIT3, we discovered FUS-DDIT3-overloaded enhancers and found that genes associated with H3K27ac/FUS-DDIT3 double-positive SEs (e.g., FST and IL8) showed high basal expression in MLPS (Fig. 2e–h). Next, by interrogating SEs in primary MLPS tissues, we identified a list of genes, including SMURF2 and ARID5B as potential FUS-DDIT3 targets whose expression were regulated through H3K27ac/FUS-DDIT3 double-positive SEs (Supplementary Tables 2 and 3). As BRD4 has displayed asymmetrical loading in SE regions, we hypothesized that FUS-DDIT3 may function together with BRD4 in regulating expression of SE-associated genes in MLPS. In support of this, we identified a physical interaction between BRD4 and FUS-DDIT3, and demonstrated further BET proteins as novel partners of FUS-DDIT3 (Fig. 2i, j and Supplementary Fig. 3i). Moreover, about 40% of BRD4 ChIP-seq peaks co-localized with FUS-DDIT3 (n = 3611) across the MLS402 genome (Fig. 2k). Silencing of BET genes resembled partially the regulatory effect of FUS-DDIT3.
Fig. 1 Super-enhancer profiling in de-differentiated LPS (DDLPS) and myxoid LPS (MLPS). a Relative rank of stitched H3K27ac ChIP-seq signals in adipocytes, mesenchymal stem cells (MSCs), DDLPS (i.e., LPS141 and LP6) cells, and MLPS (i.e., ML5402 and ML5765) cells. Representative super-enhancer (SE)-associated genes and their rankings in parentheses were highlighted. Transcription factors were marked in red. 

b Relative rank of enhancers with increasing H3K27ac signal in cells.

c Venn-diagram showing common and sample type-specific SE-associated genes across eight cell lines. Colors represent cell types.

d Relative rank of enhancers with increasing H3K27ac signal in tissues.

e-f Venn-diagram showing common and sample type-specific SE-associated genes across (e) MLPS and (f) DDLPS. SE-associated genes that were present commonly in either cell lines or fresh tumors of same subtype were compared. Source data are provided as a Source Data file.
knockdown on downstream targets (Fig. 2l). Altogether, our data reveal that FUS-DDIT3 and BET proteins cooperate to regulate expression of SE-associated genes in MLPS, and support the notion that fusion TFs hijack BET proteins for malignant transformation28.

Core transcriptional regulatory circuitry in DDLPS. Inspired from MLPS and other cellular systems1,23,24,28, SE regions are often loaded densely with lineage/disease-specific master trans-acting factors. Next, we sought to identify TFs associated with aberrant SE architectures in fusion-negative-DDLPS. By scanning known TF motifs in the SE regions of LPS141 and LP6 cells, a list of SE-associated TFs with both auto- and mutual-regulatory potentials was identified and subjected to computational reconstruction of feed-forward core transcriptional regulatory circuitry (CRC)29,30. Further, SE ranking and co-expression analysis yielded RUNX1, FOSL2, and MYC as top co-operative core TFs in both DDLPS cells and primary DDLPS tissues (Fig. 3a and
Supplementary Fig. 4a). Silencing of core TFs diminished expression of each other, which was also observed by depletion of CBFB, the heterodimeric subunit for RUNX proteins (Fig. 3b). Importantly, silencing of individual core TFs and CBFB attenuated cell viability, clonogenic growth and tumorigenicity of DDLPS cells (Fig. 3c–e and Supplementary Fig. 4b–e). To explore downstream network of core TFs, we mapped the genome-wide occupancy of FOSL2 and RUNX proteins (pan-RUNX). Half of FOSL2 and RUNX peaks were located in enhancers, capturing over 90 and 30% of SEs (Fig. 3f and Supplementary Fig. 4f), respectively. Nearly 70% of SE-associated RUNX peaks overlapped with FOSL2 signals, indicative of a collaborative activity of FOSL2 and RUNX proteins. FOSL2 and RUNX proteins co-occupied at the SE regions of all core TF genes (Fig. 3g–i and Supplementary Fig. 4g)\(^5\). Additionally, SNAI2 was identified as an important downstream target of FOSL2 and RUNX1 to reinforce the proliferative, tumorigenic, and metastatic capabilities of DDLPS cells (Fig. 3j–p and Supplementary Fig. 4h, i). Indeed, SNAI2 transcripts were significantly elevated in DDLPS samples (Fig. 3q). Higher expression of SNAI2 was associated with shorter disease-free survival of DDLPS patients (Fig. 3r). Altogether, these data identify a feed-forward transcriptional program in maintaining DDLPS malignancy.

**Involvement of BET proteins in liposarcomagenesis.** BET proteins including BRD2, BRD3, and BRD4 regulate enhancer activity and transcriptional output\(^{25,24}\). Inhibition of BET bromodomains has been impaired to appear the expression and/or activity of key oncogenic TFs (e.g., MYC, and PAX3-FOXO1)\(^{28,32,33}\). Having shown the core dependency of MLPS cells on FUS-DDIT3/BET proteins and DDLPS cells on newly identified CRC, we sought for a strategy to target these oncogenic transcriptional structures. As little is known about BET proteins in LPS, the potential functional interplays between BET proteins and disease-specific core TFs prompted us to explore their roles in liposarcomagenesis and LPS-addicted cancer.

We found that BRD2, BRD3, and BRD4 were expressed prevalently in LPS (Supplementary Fig. 5a), with BRD3 and BRD4 showing significant elevation relative to normal fat tissues. Functional assays demonstrated that BRD2/3/4 were essential for in vitro proliferation of LPS cells, including MLS402/ET, an isogenic line of MLS402, which acquired resistance to Trabectedin\(^7\) (Fig. 4a, b and Supplementary Fig. 5b–e). Silencing of BET genes also retarded subcutaneous tumor formation in a DDLPS model (Fig. 4c). Knockdown of BRD4 attenuated further distant metastasis (Fig. 4d, e). Similarly, depletion of BET genes prolonged the tumor-free survival of recipient mice in a MLS5402 model, with BRD4 knockdown reducing both incidence and burden of tumor (Fig. 4f).

To gain insights into the BET dependency, we mapped genome-wide occupancy of BRD2/3/4 proteins across LPS141 genome. BET proteins not only bound active promoters that are positive for RNA-Pol2, H3K4me3 and H3K27ac, but also marked actively transcribed genes, including all core TFs and SNAI2 (Fig. 4g–j and Supplementary Fig. 5f). Notably, 58% of overall BET-positive promoters were co-occupied by at least two BET proteins. BRD2/3/4 triple-positive genes showed the highest basal expression (Supplementary Fig. 5g, h), suggesting both co-operative and non-redundant functions of BET proteins. Meanwhile, BET proteins distributed asymmetrically to enhancers (Fig. 4k), with all SEs being loaded with at least one BET protein and SE regions of three core TF genes being co-occupied by all three BET proteins (Supplementary Fig. 5i). Hence, the widespread loading of BET proteins in active promoter and SEs implicates their extensive engagement in transcriptional dysregulation in LPS.

**Inhibition of BET proteins exerts potent anti-LPS efficacy.** Next, we determined the sensitiveness of LPS cells to BET protein-targeting agents, including four BBIs (JQ1, OTX015, I-BET151, and CPI203) and two dBETs (dBBIs and ARV-825)\(^{34,35}\) (Fig. 5a). Generally, DDLPS and MLPS cells were highly responsive, while osteosarcoma cells were least sensitive. All LPS cells except LiSa-2 showed greater susceptibilities (from fourfold to >100-fold) to ARV-825 than dBBIs and BBIs. Remarkably, MLS402/ET showed slight increase in IC\(_{50}\) of BBIs, yet remained hyper-sensitive to dBETs (Supplementary Fig. 6a). Therefore, consistent with their genetic dependency on BET family genes, LPS cells are highly vulnerable to dBETs.

ARV-825 triggered more prominent inhibition of cell cycle progression, BrdU incorporation, and anchorage-independent growth of LPS cells, relative to equimolar BBI OTX015 (Fig. 5b–e). Importantly, ARV-825 treatment at a well-tolerated dose delayed LPS xenograft development and prolonged the survival of mice bearing distal metastasis (Fig. 5f–k and Supplementary Fig. 6b). These data indicate a strong anti-LPS efficacy and therapeutic potential of ARV-825.

Mechanistically, ARV-825 induced a selective and efficient depletion of BET proteins, in contrast to the competitive interference of BET chromatin loading by OTX015 (Fig. 5i and Supplementary Fig. 6c, d). ARV-825 redirected the Cullin-RING ubiquitin ligase (CRL) CRBN to degrade BET proteins in a proteasome-dependent manner (Fig. 5m). Genetic silencing of CRBN restored growth of LPS cells even in the presence of ARV-825, which was also phenocopied by disruption of the CRL CRBN.
complex via depletion of either RBX1 or DDB136 (Fig. 5n and Supplementary Fig. 6e–h). Conversely, forced expression of CRBN rendered the cells hyper-responsive to ARV-825 (Supplementary Fig. 6i). Restoration of CRBN level in CRBN-silenced cells reversed the ARV-825 responsiveness (Fig. 5o). Thus, cellular activity of CRLCRBN is a key determinant of ARV-825 efficacy. CRBN serves a promising predictive marker for ARV-825 effectiveness.

**BET degrader disrupts oncogenic transcription.** To uncover the transcriptional responses underlying the superior activity of ARV-825 versus OTX015 in LPS cells, a comparative transcriptome analysis was performed. ARV-825 elicited a more pronounced impact than OTX015 on gene expression. ARV-825 down-regulated promoter-BET (+) genes, especially those bound with BRD4, BRD2/4, or BRD2/3/4 (Fig. 6a and Supplementary Fig. 7a). Meanwhile, ARV-825 suppressed preferentially the transcription of SE-associated genes, including FOSL2, MYC, and SNAI2, to a greater extent than OTX015 (Fig. 6b–d). Similar observations were made using dBET63,37, a different BET protein degrader, which has a distinct BET bromodomain binding moiety (Supplementary Fig. 7b–d). Interestingly, while dBET6
can inhibit RUNX1 transcription, ARV-825 reduced the half-life of RUNX1 protein (Supplementary Fig. 7e). These observations also highlight the expression dependency of core TFs on BET proteins. In MLPS cells, ARV-825 down-regulated selectively the expression of genes associated with FUS-DDIT3/H3K27ac SEs, without affecting FUS-DDIT3 level (Fig. 6e and Supplementary Fig. 7e). Echoing the effects of genetic depletion of BET genes and FUS-DDIT3, we also validated the robust inhibition of FUS-DDIT3 targets by BET-targeting agents (Fig. 6f). Remarkably, both ARV-825 and OTX015 elicited a transcriptional signature of Trabectedin response, which has been attributed to the interruption of FUS-DDIT3 function in MLPS19,20 (Fig. 6g), while other chemotherapy drugs, including docetaxel, paclitaxel, and gemcitabine showed no consistent impact on the expression of known Trabectedin-responsive genes (Supplementary Fig. 7g, h). Given the persistent dependency of Trabectedin-resistant MLPS cells on BET proteins, our data provide a strong rationale to circumvent Trabectedin-resistance via chemically induced degradation of BET proteins and suggest a new strategy to inhibit FUS-DDIT3 via scavenging co-operative BET proteins.

Discussion

In this study, we uncovered a disproportionate genomic distribution of FUS-DDIT3 and its connection to the aberrant transcriptome in MLPS. We have also identified a set of SE-driven transcriptional regulators (RUNX1, FOSL2, and MYC) that collaborate to generate interconnected feed-forward regulatory loops that reinforce the malignancy of humanDDLPS. Importantly, both the FUS-DDIT3-driven transcriptional network in MLPS and the core transcriptional regulatory circuitry in fusion-negative DDLPS are maintained by BET proteins, establishing a mechanistic basis for the promising preclinical efficacy of BET-targeting/degrading agents. These data collectively uncover a critical dependency of LPS cells on BET proteins, and provide insights into clinical translation of BET degraders (Fig. 6h).

By charting the first SE landscape in MLPS and DDLPS, our study interrogates the dysregulation of SE and SE-associated genes in liposarcomagenesis. SE-associated genes show a much higher basal expression than those with typical enhancers. Concordant with the phenotypic defect in terminal differentiation, LPS cells retain SEs of genes with known function in early adipogenesis (e.g., FOSL2238), but ablate SEs associated with adipose-definitive genes (e.g., CEBPA and PPARG). Despite the functional outputs of SE and individual enhancers remain controversial39, SE analysis helped to identify most genes with high expression and disease-relevance. The de novo SEs in LPS are likely associated with transformation, such as MYC, JUN, and CDK6. Our results encourage a more comprehensive cataloging of enhancers and SEs across LPS subtypes to understand the molecular pathogenesis in this heterogeneous group of diseases.

Although more studies are required to dissect the mechanisms of FUS-DDIT3 in transcriptional activation and repression, the overload of FUS-DDIT3 in SEs implicates its potential function in establishing aberrant epigenetic landscape. Similar to PAX3-FOX01 in rhabdomyosarcoma and EWSR1-associated fusions in Ewing sarcomas40,41, our data indicate a substantial co-localization of BRD4 and FUS-DDIT3, and a BET protein-dependent function of FUS-DDIT3 via physical interaction in MLPS. Remarkably, appreciable amounts of EWS-FL1 and EWS-ERG proteins were found in a large transcriptional complex consisting of BRD4, MED1, and RNA-Po2 in Ewing sarcoma cells.40 Either inhibition of BET protein activity or depletion of BET proteins consistently attenuated the fusion-dependent gene expression in the respective sarcoma cells.28,40,42 However, in contrast to the preferential binding of EWS-FL1 to GGAA repeats43,44, the top binding motif of FUS-DDIT3 resembled that of FOSL2 (AP-1 subunit). Altogether, these observations suggest that BET proteins are commonly hijacked by oncogenic fusion TFs for malignant transformation. As both FUS-DDIT3 and EWSR1-associated fusions involve the N-terminal domains of their respective FET proteins, exploration of whether these fusions show similar dependency on their N-terminus to recruit additional key co-factors such like FOXO1 and BAF complex would be of interest43,45.

CRC stabilizes cell-type/disease-specific transcriptional programs and controls cell identity46,47. RUNX1, FOSL2, and MYC formed a CRC in DDLPS cells maintaining their malignant growth. Expression of these core TFs showed a mutually dependent manner. As RUNX family contains three homologous proteins, functional redundancy from other RUNX proteins may also contribute to the transcriptional output of the CRC. In line with this notion, depletion of CBFB phenocopied RUNX1 deficiency, suggesting the engagement of RUNX/CBFB complex in the functionality of CRC. As the functional contribution of MYC to oncogenic transcription has been widely studied, we mainly evaluated the roles of RUNX1 and FOSL2 in DDLPS. ChiP-seq analysis revealed a marked co-occupancy of RUNX proteins and FOSL2 across SEs, supporting their collaborative activity to regulate broad downstream network involved in liposarcomagenesis. We also demonstrated the co-operative function of RUNX1 and FOSL2 in maintaining the expression of SNAI2, a key mediator of epithelial–mesenchymal transition and tumor dissemination48. For the first time, our data demonstrate that SNAI2 reinforces proliferative and metastatic capability of LPS cells and that SNAI2 expression is a promising prognostic marker for DDLPS. More studies are still required to understand the activity of SNAI2 and explore its downstream network in promoting DDLPS tumorigenesis. Moreover, BET proteins were essential to foster the expression of core TFs and their downstream targets, echoing recent findings from leukemia37. Depletion of BET proteins by two different degraders, ARV-825 and dBET6, inhibited
effectively both mRNA and protein levels of MYC, FOSL2, and SNAI2. Both degraders could downregulate RUNX1 protein, although only dBET6 blocked RUNX1 transcription. Persistent RUNX1 transcription under ARV-825 treatment may be associated with unrecognized probe-specific activity/property of ARV-825. Other factors such like gene length may also affect the transcriptional output of downstream targets in response to BET depletion. Despite different mechanisms, both ARV-825 and dBET6 attenuated the expression of RUNX1 protein. Altogether, our data support the concept that BET proteins is a potential Achilles’ heel that could be targeted to disrupt the core oncogenic transcriptional programs.

Importantly, our study uncovered the essential roles and desirable therapeutic potentials of BET proteins in LPS.
Degradation of BET proteins and inhibition of bromodomain elicited distinct cellular and transcriptional responses, implying differential reliance of LPS cells on BET protein function and bromodomain activity. Consistent with the genetic dependency of LPS cells on BET proteins, depletion of BET proteins by ARV-825 accounted for its superior anti-cancer efficacy. BET protein inhibition/depletion mainly triggered a cytostatic effect in established LPS cell lines, similar to previous studies in established glioblastoma cells and established osteosarcoma cells. Apart from anti-proliferative activities, BET protein-targeting agents have also been reported to induce apoptosis in a number of cancer cells, including primary osteosarcoma cells, breast cancer cells, and many types of hematopoietic malignancies. Although we and others have demonstrated that BET protein degraders or inhibitors can effectively suppress the expression of SE-driven MYC, BET protein perturbation had negligible effect on MYC protein in osteosarcoma cells. These heterogeneous responses may be associated with differential intrinsic dependencies on BET proteins and cell-type-specific genomic/transcriptional abnormalities. While our study provides one mechanism to explain the LPS-specific BET protein dependency and its connection to LPS-promoting CRC, main targets of BET proteins are likely different in other cancers lacking FUS-fusions or 12q amplicons. Stubbs et al. evaluated the BET protein-regulated kinase network in myeloma models, and provided an insightful strategy of combinatorial inhibition of BET proteins and their downstream kinases to achieve optimal anti-cancer impact. Hence, BET protein-targeting agents may target distinct downstream molecules in different cancers. Integrative analysis of BET protein-dependent transcriptional network and key other pathways serves as a promising approach to tackle the heterogeneous responses to BET protein-targeting agents in human cancers. Remarkably, MLPS cells with acquired resistance to Trabectedin remained vulnerable to both genetic and chemical depletion of BET proteins, thus highlighting the potential of targeting BET protein dependency to overcome clinical insensitivity to Trabectedin. In addition, we identified CRBN as a promising predictive marker for ARV-825 efficacy across different sarcoma cells and found alternative factors that may impair ARV-825 efficacy, including co-factor expression and proteasomal activity. Collectively, this study reveals the BET protein-dependent core transcriptional programs that are targetable by BET protein-degrading agents in LPS.

Methods

Cell culture. All cell lines tested negative for mycoplasma and are not listed in the ICLAC database. Human embryonic kidney cells 293T (HEK293T, ATCC), U2OS (U-2 OS, ATCC), and MG63 (MG63, ATCC) were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Biowest). MSL042 (MSL 402-91), MSL1765 (MSL 1765-92) and GOT-3 cells were generously provided by Dr. Pierre Amar [32, 33]. LPS and LPS141 cells were provided by Dr. Christopher DM Fletcher [26], T778 and T1000 cells were kind gifts from Dr. Florence Pedeutour. MSL042/ET, FU-DDLS-1,57, and LiSa-2 cells were gifts from Dr. Eugenio Erba, Dr. Jun Nishio, and Dr. Peter Möller, respectively. All LPS cells were maintained in Roswell Park Memorial Institute medium 1640 (RPMI-1640, Biowest). All aforementioned cell lines were also supplemented with 10% fetal bovine serum (FBS, Biowest) and 1% penicillin-streptomycin (Gibco) in a humidified incubator at 37 °C. All cell lines were authenticated by short tandem repeat analysis with the Geneprint 10 System Kit (Promega). U2OS and MG63 were authenticated with 100% identity to the respective reference cell line in DSMZ database. LPS cell lines reported in this study did not match any known cell lines in the reference databases, including ATCC, DSMZ, Riken, JCRB, and KCLB.

Plasmids and reagents. All pLKO.1-based short hairpin RNA (shRNA) vectors and lentiviral vectors were listed in Supplementary Table 4. SHC002 was used as non-targeting control (sh-Control). Stable knockdown cell lines were generated by lentiviral infection followed by puromycin (Sigma-Aldrich) selection. pLX304 vector control was a gift from Dr. David Rose [56]. pLX03-CRBN-V5 was purchased from DNASU Plasmid Repository. Plasmids expressing GFP-tagged BET proteins, and FUS-DDIT3 were gifts from Drs. Kyle Miller, and David Ron, respectively. FLAG-BRD3 and HA-FUS-DDIT3 constructs were generated in this study via ligation-dependent molecular cloning into pcDNA3.1 (+) vector. SMART-pool small-interfering RNAs (siRNAs) against DDIT3, BRD2, BRD3, CRBN, MYC, FOSL2, RUNX1, and CBFB were purchased from GE Dharmacon. ON-TARGETplus Non-targeting Pool (D-001810-10-05) was used as negative control. siRNAs were transfected using RNAiMAX (Life Technologies). The sources of other key chemicals used in this study are listed in Supplementary Table 5.

Cell viability assay. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed to measure cell viability under indicated treatment. Briefly, cells were seeded into 96-well plates at 2000–3000 cells/well and cultured for the specified period. At the end of experiment, MTT substrate (Sigma-Aldrich) was added into each well and incubated for 3 h. After careful removal of medium and addition of 100 µL of MTT STOP solution, plates were shaken on a microplate shaker for 3 h and read on a Tecan microplate reader with the absorbance at 570 nm. IC50 values were measured by MTT assay after 96-hour treatment (n = 3).

Brdu incorporation assay. BedU Cell Proliferation Assay Kit (BioVision Inc.) was used according to the manufacturer’s instruction. LPS cells were seeded into 96-well plates at 5000 cells/well and treated with indicated compounds for 24 h. BrdU solution was then added into each assay well and incubated at 60 °C for 3 h before fixation. BrdU incorporation by proliferating cells was detected by an enzyme-linked immunosorbent assay.

Cell cycle analysis. Cells receiving indicated treatment were trypsinized, washed, and fixed in 70% ethanol at 4 °C. Cells were washed with cold phosphate-buffered saline (PBS), resuspended in propidium iodide solution containing RNase A, and incubated at 37 °C for 30 min. After measurement by LSR II Flow Cytometer System (BD Biosciences), cell cycle distribution was analyzed by Flowjo software.

Soft agar colony formation assay. Soft agar colony formation assay was performed to evaluate the anchorage-independent growth of LPS cells with indicated treatment. Basal layer was prepared by adding 500 µL of 0.4% (w/v) agar (RPMI supplemented with 10% FBS) into 12-well plates. After basal layer solidified, 1000–5000 LPS cells were mixed with 500 µL of top layer solution (0.4% low melting agarose in RPMI supplemented with 10% FBS) and dispersed over the basal layer. Plates were placed at 4 °C for 25 min before addition of feeder medium (1 mL) into each well, and then kept at 37 °C in a 5% CO2 incubator for 2 weeks. Colonies were stained using 0.01% crystal violet in 4% paraformaldehyde/PBS.

Animal models. All animal experiments were in compliance with ethical regulations of the NUS Institutional Animal Care and Use Committee. Subcutaneous
A xenograft model was employed to evaluate the tumorigenicity of LPS cells upon either genetic manipulation or chemical treatment. Indicated amount of LPS cells were mixed with 100 µL of Matrigel (Corning)/PBS solution (volume ratio, 1:1) and injected subcutaneously on the upper flanks of NOD/SCID gamma mice (6- to 8-week-old). For in vivo ARV-825 treatment, mice bearing palpable DDLPS xenografts were randomized into two groups. Mice in experimental arm received ARV-825 at a dose of 5 mg/kg by intraperitoneal (i.p.) injection once a day, 5 days per week; animals in the control arm received the same volume of vehicle (5% Solutol/Kolliphor® HS 15 in PBS). Tumor size was measured by caliper and tumor volume (mm³) was estimated according to formula 1/2(Length × Width²). Xenografts were dissected and weighed upon harvest.

Experimental metastasis assays via intravenous injection of LPS cells were performed to study genes that regulate metastatic progression. LPS141 cells with indicated genetic manipulation were injected (0.1 million per injection) via tail vein
Fig. 5 ARV-825 redirects CRiCRBN to disrupt BET protein dependency of liposarcoma (LPS). a Heatmaps for the mean IC50 values of BET-targeting agents in LPS and osteosarcoma (U2OS, MG63, and LiSa-2) cells treated with the maximum dose (1 μM) and were set as 1 μM for heat map illustration. b Chemical structure of ARV-825. c, d Effects of ARV-825 and OTXO15 treatments on c cell cycle progression and d cellular BrdU incorporation in LPS141 cells (200 nM, 24 h). e Dose-dependent inhibition of clonogenicity of LPS cells on soft agar by either ARV-825 or OTXO15. f-h Effect of ARV-825 treatment on f animal body weight (n = 5), g xenograft volume (n = 10), and h weight of LPS141 xenografts at endpoint (n = 10). i Effect of ARV-825 treatment on weight of endpoint xenografts from L6P and JM5402 (n = 8). k Effect of ARV-825 treatment on overall survival time of mice-bearing distant metastasis of LPS141 cells (n = 7). Temporal effects of ARV-825 and OTXO15 (200 mM) on indicated proteins in LPS141 cells. m Effect of MG132 on the ability of ARV-825 to deplete BET proteins. LPS141 cells were treated with MG132 (5 μM) and/or ARV-825 (200 μM) for 8 h before harvest. n Effects of CRBN, DDB1, and RBX1 silencing on the anti-proliferative efficacy of ARV-825 in LPS141 cells. o Ecotrophic CRBN expression in CRBN-silenced cells reversed insensitivity to ARV-825. Data of c-j, n, and o represent mean ± SEM; n = 3 in c-e, n, and o. One-way analysis of variance (ANOVA) was applied for c-e; Student’s t-test (two-tailed) was applied in g-j; log-rank test was applied in k. Source data are provided as a Source Data file.

into the NOD/SCID gamma mice (6- to 8-week-old). Three weeks after implantation, recipient mice were sacrificed for examination of metastatic nodules in lung and liver. For the study of ARV-825 treatment in a metastatic model, mice were injected intravenously into the tail vein with 0.5 million of LPS141 cells, and subsequently randomized into two groups. Treatments with either vehicle or ARV-825 (5 mg/kg, once a day, six times per week) were initiated 4 days after cell injection. Animal survival was recorded using 10% loss of peak body weight as a humane endpoint criterion.

No specific randomization method was used to allocate mice into different treatment groups, and groups were allocated to allocation during experiments or outcome assessment. Minimum sample sizes for individual experiments were determined not on the basis of a statistical method, but according to (n = 7). No animal was excluded from these experiments.

Cell lysate preparation and immunoblot assay. Whole-cell extracts were prepared by incubating cells in lysis buffer (50 mM Tris pH 8.0, 420 mM NaCl, 5% glycerol, 0.1% NP-40, 0.1 mM EDTA) with fresh addition of 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1x protease inhibitor cocktail (Roche), 1x phosphatase inhibitor cocktail (Roche), 1 mM MgCl2 and Benzonase (1:500, Novagen) for 20 min on ice. To extract chromatin-bound proteins, cell pellet was lysed by CSK buffer (10 mM PIPES, pH 6.8, 300 mM sucrose, 100 mM NaCl, 1 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 0.5% Triton X-100) supplemented with protease and phosphatase inhibitors. After centrifugation, non-chromatin soluble fraction was enriched in the supernatant. Insoluble pellet was washed twice with CSK buffer, re-suspended in lysis buffer, sonicated, and digested with Benzonase for 20 min on ice. Clear supernatant after centrifugation (13,000 rpm, 10 min) represented the chromatin fraction. Protein concentration was quantified by Bradford assay. Immunoblot analysis was conducted following standard protocol with indicated antibodies listed in Supplementary Table 6. Uncropped scans of immunoblots are included in Supplementary Table 6.

Immunoprecipitation (IP). To prepare cell lysate for either IP or Co-IP, cell nuclei were isolated and lysed in IP buffer (25 mM Tris pH 8.0, 0.15 M NaCl, 2.5% glycerol, 0.05% NP-40, 0.1 mM EDTA) with fresh addition of 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1x protease inhibitor cocktail, 1 mM MgCl2 and Benzonase (1:500, Novagen). M2 Sepharose beads (Sigma-Aldrich), GFI-Trap® beads (ChromoTek), and Pierce® Anti-HA Agarose (Thermo Fisher Scientific) were used for IP of proteins with FLAG-Tag, GFP-Tag, or HA-Tag, respectively. For endogenous IP, one milligram of nuclear extract was incubated overnight with magnetic beads (Invitrogen Dyna-beads) conjugated with respective antibodies. Bound proteins were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS/PAGE) and immunoblot. Primary antibodies for IP assays were listed in Supplementary Table 6.

Chromatin immunoprecipitation (ChIP) and ChIP-seq analysis. Pathologically reviewed human LPS samples were collected from Neurosurgical Tissue Repository. The study of human LPS samples was approved by the NUS Institutional Review Board (reference code N-17-057). ChIP was performed by following a standard protocol. Briefly, either homogenized tissues or cells were fixed with 1% formaldehyde for 10 min at room temperature, followed with three washes using cold PBS. Nuclei were extracted and re-suspended in SDS lysis buffer for 10 min on ice before sonication by Bioruptor (Diagenode). Optimal condition of sonication yielded genomic fragments around 200 to 500 bp. After sonication, cell debris was removed by centrifugation (13,000 rpm, 10 min). Supernatant was then pre-cleared and incubated with magnetic beads (Invitrogen Dynabeads) conjugated with specific antibodies (Supplementary Table 6). After overnight incubation, magnetic beads were washed twice with cold TBS followed by high salt wash buffer, LiCl wash buffer, and TE buffer. Bound DNA was eluted, reverse-crosslinked, and purified by QiAquick PCR purification kit (Qiagen). ChIP-seq library was constructed using TruSeq® DNA-seq Kit (Rubicon Genomics) following standard protocols, and subjected to Illumina deep sequencing (see below).

For ChIP-seq data analysis, raw reads were aligned to hg19 reference genome using bowtie aligner followed by removal of PCR duplicates with Picard markDuplicates utility. Resulting bam files were used for peak calling with MACS2 by extending reads to 200 bp. ChiP signals (Bedgraph) were simultaneously generated and input signal was subtracted with MACS2 bedmp function. Bedgraphs were later converted to bigwig files with UCSC BedGraphToBigWig utility. Alignment and peak calling pipelines with hard-coded parameters are available at https://github.com/PoisonAlien/chiqht. Detected peaks were annotated with HOMER annotatePeaks. Denovo motif identification and comparison were also performed with HOMER using findMotifsGenome program. Heatmaps were drawn using deuconv tool by centering either on identified peaks or on transcripts in the nearest site (TSS). mRNA gene expression profiles were generated and visualized based on transcription direction in heatmaps or metagene plots where – and + indicated upstream and downstream of TSS, respectively, of genomic regions after alignment with transcription direction. RNA-Pol2 pausing index was estimated based on RNA-Pol2 Chip-seq data and calculated as a ratio of TSS region and gene profile plots. Signal ≥200 bp of peak center were extracted for every 25 bp bin using bwtool matrix function. Average signal was estimated and plotted in R. ChiP-seq data of adipocytes (GSE59703; sequence length = 50) and mesenchymal stem cells (GSE16256; sequence length = 36) have been published previously.

The ROSE (Rank Ordering of Super-Enhancers) algorithm (https://bitbucket.org/young_computational_rose) was used to call super-enhancers (SEs). Regions within +/− 1250 bp from TSS were excluded for this analysis. Input-subtracted ChiP-seq signals were stitched and ranked based on intensity. A geometrical inflection point was used as cutoff to separate SEs from typical enhancers. SE-association was annotated with DESeq2 with lfc>0.5 and fdr<0.05. Figure rank and stitched H3K27ac signals were normalized within each sample. Specifically, x-axis was normalized by calculating the Relative enhancer rank; y-axis was normalized by calculating the Percentage of H3K27ac signal in enhancer (as indicated by the following equation). Relative enhancer rank = (Enhancer rank of individual stitched enhancer)/(Number of SE and TE identified in each sample). Percentage of H3K27ac signal in the enhancer = 100 x (Sum of H3K27ac signal in each stitched enhancer)/(Sum of H3K27ac signal in all SE and TE). For PCA and hierarchical clustering analysis, ChiP signals for all SEs identified across samples were estimated (area under the peak) followed by log transformation. PCA was performed with prcomp function. Same data were used for Hierarchical clustering with hclust function. Core transcriptional regulatory circuitries were computationally inferred by CRCmapper based on scanning of TF motifs within SEs. The peak distribution of FUS-DDIT3, pan-RUNX, FOSL2, and BET proteins across cis-regulatory regions of the genome was annotated as below: peaks that localized within −1000 to +200 bp from the TSS were defined as Promoter-bound; those present inside either SEs or typical enhancers were defined as Enhancer-bound; remaining peaks were considered as others.

RNA preparation, qRT-PCR, RNA-seq, and expression analysis. Total RNA was extracted by RNasy Kit (Qiagen) and treated with DNase. cDNA library for quantitative reverse transcription PCR (qRT-PCR) was prepared by ReverTraAce RT Reverse Transcription Kit (Thermo Fisher Scientific). qPCR was conducted with Kapa SYBR fast qPCR Master Mix (KAPA Biosystems) on a 7500 Real-time PCR System (Applied Biosystems). qRT-PCR primers are listed in Supplementary Table S3.

RNA-seq library was constructed by TruSeq Library Prep Kit (Illumina) and sequenced at BGI Tech Solutions Co., Ltd. (Herseq, paired-end reads of 100 bases). Paired-end reads were pseudo-aligned and quantified to Ensemble (hg19; version 88) transcripts using kallisto program. Kallisto results were imported into DEseq2 using tximport Bioconductor package. Differential gene expression analysis was performed using DEseq2 with lfc>0.5 and fdr<0.25. Expression values were calculated in terms of FPKM for every gene with DESeq2: FPKM function. Gene set enrichment analysis (GSEA) was performed on all active genes (mean FPKM >0.5). Transcriptsome data for TCGA samples of Sarcoma cohort (TCGA-SARC, n = 57) were downloaded using TCGA2Biolinks Bioconductor package via GDC (data freeze from Dec 2017). Gene Expression Matrix files for microarray dataset GSE11129 were downloaded using GEOquery Bioconductor package. Gene
expression for probes mapping to same genes were averaged to get gene level expression for downstream analysis.

Statistical analysis. Unless otherwise stated, two-tailed Student’s t-test was used to analyze the statistical difference between two groups, while one-way analysis of variance (ANOVA) was applied for multi-group comparison. Log-rank test was used for survival analysis. n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001. Sample sizes were not predetermined statistically. Center values, error bars, and number of replicates are described in the corresponding figures and/or figure legends. Replicates represent: (1) separate tumors in xenograft assays; (2) individual animals in experimental metastasis assays, and (3) independent biological repeats for in vitro assays.

Fig. 6 BET protein degrader destroys the core transcriptional programs in liposarcoma (LPS). a Differential responses of genes to OTX015 and ARV-825 treatment according to BET protein occupancy around their promoter-proximal regions in LPS141 cells. BET(+) denotes genes with at least one ChIP-seq peak of BET proteins within their promoter-proximal regions; BET(−) denotes genes that are negative for binding of BET proteins. b Differential responses of genes to OTX015 and ARV-825 treatment according to enhancer status in LPS141 cells. c Quantitative reverse transcription PCR (qRT-PCR) analysis showing the mRNA levels of core TF genes, SNAI2, and CDKN1A upon ARV-825 and OTX015 treatment (200 nM, 24 h) in LPS141 cells. CDKN1A was used as positive control for differentially expressed genes. d Immunoblot analysis showing the impact of ARV-825 and OTX015 (200 nM, 24 h) on levels of BET proteins, core Tfs, and SNAI2 in LPS141 cells. e Differential responses of genes to OTX015 and ARV-825 treatment (200 nM, 24 h) according to their enhancer occupancy by FUS-DDIT3 in MLS402 cells. f qRT-PCR analysis showing the mRNA levels of FST, IL8, BCA1, and CDKN1A upon ARV-825 and OTX015 treatment (200 nM, 24 h) in MLS402 cells. CDKN1A was used as positive control for differentially expressed genes. Data are presented as mean ± SEM; n = 3. g GSEA plots of Trabectedin response pathway in MLS402 cells treated with dimethyl sulfoxide (DMSO) versus ARV-825 or OTX015. h Models of BET protein-dependent core transcriptional programs in myxoid LPS (MLPS) and de-differentiated LPS (DDLPS). Depletion of BET proteins serves as a common strategy to target these core transcriptional dependencies. Box plots indicate median value (center line), first and third quartiles (box limits), as well as minimum and maximum values (whiskers) after excluding outliers (dots). Wilcoxon signed-rank test was applied for a, b, e; one-way analysis of variance (ANOVA) was applied for c, f. n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001. Source data are provided as a Source Data file.
10. Kanojia, D. et al. Genomic landscape of liposarcoma.

12. Dickson, M. A. et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified liposarcoma: an exploratory proof-of-mechanism study.

11. Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of soft tissue sarcomas.

9. Barretina, J. et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.

7. Uboldi, S. et al. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylation agents. Int. J. Cancer 131, 59–69 (2012).

2. Fletcher, C. D. M., Bridge, J. A., Hogendoorn, P. C. W. & Mertens F. WHO classification of Tumours of Soft Tissue and Bone 947 (2013).

13. Ray-Coquard, I. et al. Effect of the MDM2 antagonist RG7112 on the P53 independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells. Sci. Rep. 5, 2024–2038 (2015).

18. D’Incalci, M. & Galmarini, C. M. A review of trabectedin (ET-743): a unique drug for the treatment of soft tissue sarcomas. J. Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol. 27, 163–174 (2009).

14. Knight, J. C., Renwick, P. J., Dal Cin, P., Van den Bergh, H. & Fletcher, C. D. Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. Cancer Res. 55, 24–27 (1995).

15. Antonescu, C. R. et al. Monochlonality of multifocal myxoid liposarcoma: confirmation by analysis of TLS-CHOP or EWS-CROH rearrangements. Clin. Cancer Res. 6, 2788–2797 (2000).

16. Grosso, F. et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 8, 595–602 (2007).

17. Kawai, A. et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoid: a randomised, open-label, phase 2 study. Lancet Oncol. 16, 406–416 (2015).

18. D’Incalci, M. & Galmarini, C. M. A review of trabectedin (ET-743): a unique mechanism of action. Mol. Cancer Ther. 9, 2157–2163 (2010).

19. Di Giandomenico, S. et al. Epigenetic characterization of trabectedin-resistant myxoid liposarcoma. Oncogene 33, 5201–5210 (2014).

20. Forni, C. et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol. Cancer Ther. 8, 449–457 (2009).

21. Keung, E. Z. et al. Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma. J. Clin. Invest. 125, 2965–2975 (2015).

22. Hnizd, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934–947 (2013).

23. Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320–334 (2013).

24. Chapuy, R. et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 24, 777–790 (2013).

25. Perez-Salvia, M. & Esteller, M. Bromodomain inhibitors and cancer therapy: From structures to applications. Epigenetics 12, 323–339 (2017).

26. Beertsema, E. et al. The NIH roadmap epigenomics mapping consortium. Nat. Biotechnol. 28, 1045–1048 (2010).

27. Loiz, A. et al. Browing of human adipocytes requires KLF11 and reprogramming of PPARgamma superenhancers. Gene Dev. 29, 7–22 (2015).

28. Gryder, B. E. et al. PAX3-FOXO1 establishes myogenic super enhancers and overrides BET bromodomain vulnerability. Cancer Discov. 7, 884–899 (2017).

29. Saint-Andre, V. et al. Models of human core transcriptional regulatory circuits. Genome Res. 26, 385–396 (2016).

30. Huang, M. et al. dBCoRC: a database of core transcriptional regulatory circuits modeled by H3K27ac ChIP-seq signals. Nucl. Acids Res. 46, D71–D77 (2018).

31. Falco, C. et al. Systematic mapping of functional enhancer-promoter connections with CRISPR interference. Science 354, 769–773 (2016).

32. Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cancer Cell 31, 904–911 (2017).

33. Xu, L. et al. Targetable BET proteins- and EZF1-dependent transcriptional program maintains the ubiquity of glioblastoma. Proc. Natl Acad. Sci. USA 115, E5086–E5095 (2018).

34. Winter, G. E. et al. Drug development. Pthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376–1381 (2015).

35. Lu, J. et al. Hijacking the E3 ubiquitin ligase Cereblon to efficiently target BRD4. Chem. Biol. 22, 755–763 (2015).

36. Fischer, E. S. et al. Structural dynamics of the DDR1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512, 49–53 (2014).

37. Winter, G. E. et al. BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment. Mol. Cell 67, 5–18 e19 (2017).

38. Siersbaek, R. et al. Transcription factor cooperativity in early adipogenic hotspots and super-enhancers. Cell Rep. 7, 1443–1455 (2015).

39. Dukler, N., Gulko, B., Huang, Y. F. & Sipek, A. Is a super-enhancer greater than the sum of its parts? Nat. Genet. 49, 2–3 (2014).

40. Gollavelli, P. N. et al. EWS-ET1 driven ewing sarcoma requires BET bromodomain proteins. Cancer Res. 78, 4760–4773 (2018).

41. Tomaszou, E. M. et al. Epigenetic mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLINI. Cell Rep. 10, 1082–1095 (2015).

42. Loganathan, S. N. et al. BET bromodomain inhibitors suppress EWS-FLINI dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Oncotarget 7, 43504–43517 (2016).

43. Shirinqui, E. et al. EWS-FLINI regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma. Cancer Sci. 109, 2907–2918 (2018).

44. Riggi, N. et al. EWS-FLINI utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell. 26, 686–681 (2014).

45. Boulay, G. et al. Cancer-specific retargeting of BAF complexes by a prion-like domain. Cell 171, 163–178 e119 (2017). BAF170-D1R regulates a transcriptional program that cooperates with Foxq1 in mouse Ewing sarcoma. Cancer Sci. 109, 2907–2918 (2018).

46. Bae, T. et al. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell. 22, 209–221 (2012).

47. Boyer, L. A. et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122, 947–956 (2005).

48. Casas, E. et al. Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res. 71, 245–254 (2011).

49. Baker, E. K. et al. BET inhibitors induce apoptosis through a MYC independent mechanism and synergy with CDK inhibitors to kill osteosarcoma cells. Sci. Rep. 5, 10120 (2015).

50. Lee, D. H. et al. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. Int. J. Cancer 136, 2055–2064 (2015).

51. Bai, L. et al. Targeted degradation of BET proteins in triple-negative breast cancer. Cancer Res. 77, 2476–2487 (2017).

52. Stubbs, M. C. et al. The novel bromodomain and extraterminal domain inhibitor INCB054329 induces vulnerabilities in myeloma cells that inform rational combination strategies. Clin. Cancer Res., https://doi.org/10.1158/1078-0432.CCR-18-0098 (2018).

53. Persson, F. et al. Characterization of the 12q amplification: A high-resolution, oligonucleotide array CGH and expression analyses of a novel liposarcoma cell line. Cancer Lett. 260, 37–47 (2008).

54. Accara, P. et al. Rearrangement of the transcription factor gene CHOP in myxoid liposarcoma with t(12;16)(q13;p11). Genes Chromosomes Cancer 5, 278–285 (1992).
55. Thelin-Jarnum, S., Lassen, C., Panagopoulos, I., Mandal, N. & Aman, P. Identification of genes differentially expressed in TLS-CHOP carrying myxoid liposarcomas. *Int. J. Cancer* **83**, 30–33 (1999).

56. Snyder, E. L. et al. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. *J. Pathol.* **218**, 292–300 (2009).

57. Nishijo, J. et al. Establishment of a novel human dedifferentiated liposarcoma cell line. *FU-DDLS-1: conventional and molecular cytogenetic characterization*. *Int. J. Oncol.* **22**, 535–542 (2003).

58. Wabitsch, M. et al. LiSa-2, a novel human liposarcoma cell line with a high capacity for terminal adipose differentiation. *Int. J. Cancer* **88**, 889–894 (2000).

59. Yang, X. et al. A public genome-scale lentiviral expression library of human ORFs. *Nat. Methods* **8**, 659–661 (2011).

60. Gong, F. et al. Screen identifies bromodomain protein ZMYND8 in chromatin recognition of transcription-associated DNA damage that promotes homologous recombination. *Gene Dev.* **29**, 197–211 (2015).

61. Crozat, A., Aman, P., Mandal, N. & Ron, D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. *Nature* **363**, 640–644 (1993).

62. Xu, L. et al. BCL6 promotes glioma and serves as a therapeutic target. *Proc. Natl Acad. Sci. USA* **114**, 3981–3986 (2017).

63. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.* **10**, R25 (2009).

64. Ramirez, F., Dunbar, F., Dierli, S., Grunen, B. A. & Manke, T. DeepTools: a flexible platform for exploring deep-sequencing data. *Nucl. Acids Res.* **42**, W187–191 (2014).

65. Pohl, A. & Beato, M. Bwtool: a tool for bigWig files. *Bioinformatics* **30**, 1618–1619 (2014).

66. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. *Nat. Biotechnol.* **34**, 525–527 (2016).

67. Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. *F1000Res.* **4**, 1521 (2015).

68. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).

69. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl Acad. Sci. USA* **102**, 15545–15550 (2005).

Acknowledgements

We thank Takaomi Sanda for kind suggestions, Linda Shye-Huey Chuang and Vaidhe Krishna for reagent sharing, and Hao-Qing Shen, Fang Hu, and Hazimah Binte Mohd Nordin for help with experiments. This work is funded by the National Institute of Health (R01-CA200992-03), National Research Foundation Singapore under its Singapore Translational Research (STAR) Investigator Award to H.P.K. (NMRC/STAR/0021/2014), the Singapore Ministry of Education Academic Research Fund Tier 2 (MOE2013-T2-2-150, MOE2017-T2-1-033), the Singapore Ministry of Health’s National Medical Research Council (NMRC) Center Grant awarded to National University Cancer Institute of Singapore (NCIS), the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centers of Excellence initiatives, and is additionally supported by NMRC Open Fund Young Individual Research Grant (MOH-OFYIRG18May-0001) to L.X., a Seed Funding Program within the NCIS Center Grant, a NCIS Yong Siew Yoon Research grant through donations from the Yong Loo Lin Trust, and the Wendy Walk Foundation. J.C. is supported by Start-up Grant of HZNU (4125CS021820470) and National Natural Science Foundation of China (81802338). The computational work for this study was partially performed on resources of the National Supercomputing Center, Singapore (https://www.nscc.sg).

Author contributions

Conceptualization: Y.C., L.X. and H.P.K.; Methodology: Y.C., L.X. and H.P.K.; Visualization: Y.C., L.X., A.M., M.-L.H., P.D. and R.Y.-T.L.; Investigation: Y.C., L.X., A.M., M.-L.H., D.K., T.Z.T., P.D., R.Y.-T.L., X.-Y.K., J.W.S., J.C., L.-W.D., Y.-Y.J. and B.C.G.; Writing-original draft: Y.C. and L.X.; Writing and editing: Y.C., L.X., A.M., T.Z.T. and H.P.K.; Funding acquisition: L.X., B.C.G. and H.P.K.; Resources: Y.C., L.X., D.K., J.W.S., S.G., A.P., M.E.P. and H.P.K.; Supervision: H.P.K.

Additional information

Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-019-09257-z.

Competing interests: The authors declare no competing interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

Journal peer review information: Nature Communications thanks Berkley Gryder and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.